S5 -E1.5 - SurfingMASH Is Back! How Will GLP-1 Ads From Telemedicine Affect MASH?

Send us Fan MailAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of telemarketer-driven consumer advertising for GLP-1 agents as anti-obesity medicines and asks what impact this might have on diagnosis, treatment and monitoring of MASH in the US. Specifically, the participants discuss the potential impact and concerns surrounding the use of weight-loss drugs, including semaglutide, and the impending approval of drugs for treating fatty liver disease. They highlight the challenge of ensuring patients receive comprehensive care that includes liver health assessments, especially with the rise of telemedicine and commercial approaches to medication distribution. The dialogue underscores the necessity of educating healthcare providers beyond physicians, such as Allied Health professionals, to have informed discussions about these medications and their management.The discussion also delves into the issues of drug pricing, the black market for medications, and the importance of proper education for all healthcare providers to prevent misuse and ensure the right patient populations are being treated. Jörn Schattenberg notes the significance of preparing for drugs that are weight neutral, addressing the obesity epidemic without exacerbating liver disease issues. He emphasizes the need for specialists to assess treatment responses and manage patient care effectively.Roger Green expresses concerns about the commercialization of healthcare leading to suboptimal patient education and care, particularly in the context of obesity treatment. He plans to engage with payers to discuss the implications of new treatments on healthcare systems.Louise Campbell raises questions about drug-drug interactions and the broader implications of new treatments being prescribed outside their intended patient populations. Jörn reassures that no major issues were identified in clinical trials regarding drug-drug interactions and believes that standard clinical practices can manage any potential concerns.The conversation reflects a complex landscape of treating liver and obesity-related conditions, highlighting the need for comprehensive education, careful patient assessment, and a multidisciplinary approach to healthcare in the face of new and emerging treatments.